Who Paid My Doc
Stockton Mayer
Infectious Disease Chicago, IL Doctor of Osteopathy
NPI 1114193240 CMS profile 1309046
808 S Wood St, Room 888 Mc 735, Chicago, IL 60612
General payments
$3,877
Research payments
$142,315
Ownership & investment interest
$0
Research they led as principal investigator
$45,434
Through program year 2025, Stockton Mayer of Chicago, IL is reported in the CMS Open Payments database as having received $3,877 across 16 general payments and $142,315 in research payments paid to them. Separately, studies naming them as principal investigator received $45,434 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,461 | 5 | |
| 2024 | General | $30 | 1 | |
| 2023 | General | $1,321 | 6 | |
| 2022 | General | $42 | 2 | |
| 2021 | General | $11 | 1 | |
| 2021 | Research | $138,450 | 1 | |
| 2020 | Research | $3,865 | 1 | |
| 2019 | General | $13 | 1 |
Beside peers
- Stockton Mayer
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Stockton Mayer were reported at $2,461. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Stockton Mayer | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $11 | $148 | $38–$905 | $132 |
| 2022 | $42 | $166 | $50–$834 | $149 |
| 2023 | $1,321 | $171 | $57–$787 | $160 |
| 2024 | $30 | $176 | $52–$752 | $164 |
| 2025 | $2,461 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
337
Drug cost
$706,586
Branded share of claims
70.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 73 | $308,589 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 22 | $94,797 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 15 | $61,685 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 17 | $55,900 | |
| Tivicay Dolutegravir Sodium | Brand | 23 | $55,390 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 11 | $37,110 | |
| Prezcobix Darunavir/Cobicistat | Brand | 13 | $30,734 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 13 | $29,121 | |
| Darunavir | Generic | 19 | $16,757 | |
| Efavirenz | Generic | 14 | $11,110 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$3,309
Medicare patients
33
Services billed
49
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 58% | |
| Diabetes | 52% | |
| Heart failure | 36% | |
| Ischemic heart disease | 36% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
18 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Illinois
Related records
Infectious Disease in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.